Contents 3 min read
2026-11-11 correction: Cell, mouse and human findings were separated. The CoQ10 trial and research-dose context were clarified; the unverified mitochondrial treatment scheme was removed.
Explore CoQ10, PQQ, NMN and creatine research; mitochondrial mechanisms do not explain every cause of brain fog or guarantee supplement benefits.
Mitochondria and Brain
Mattson's 2008 narrative review discusses neuronal ATP production, calcium and redox signaling, and mitochondrial movement. Beal 2004 discusses mechanistic rationales for mitochondria and CoQ10 in neurodegeneration. These are not new randomized supplement trials; a mechanism does not establish treatment success in a patient. [1] [2]
Brain fog, concentration problems and fatigue do not by themselves diagnose mitochondrial dysfunction. These symptoms can have different causes; mechanistic research does not establish an individual need for supplements. Persistent symptoms or impairment of daily function warrant clinical assessment.
Coenzyme Q10
QE3 2014: 600 early Parkinson patients were assigned placebo, 1200 or 2400 mg/day CoQ10; all received 1200 IU/day vitamin E. Stopped at a prespecified futility criterion. UPDRS worsening was 6.9, 7.5 and 8.0 points respectively; no clinical benefit. [4]
High research doses tolerated in this patient group are not personal safe upper limits. Results support neither Parkinson treatment nor healthy cognitive-enhancement advice; vitamin E context is retained.
PQQ
Chowanadisai 2010: Mouse liver-derived Hepa1-6 cells were studied with 10–30 µM PQQ for 24–48 hours. Some mitochondrial-content and respiration measures increased; CREB and PGC-1α pathways were investigated. This laboratory result does not establish that oral PQQ increases mitochondria in human brains or improves cognition; culture concentration is not a human dose. [7]
NMN
Mills et al. (2016) reported improvements in selected age-associated metabolic and physiological measures after 12 months of NMN administration in C57BL/6N mice. [3]
Changes in mouse physiological measures do not establish longer human lifespan or cognitive benefit. This experiment cannot provide a safe human anti-aging protocol.
Yoshino 2021: 25 postmenopausal women with prediabetes and overweight/obesity completed a 10-week randomized double-blind trial: 12 received placebo and 13 received 250 mg/day NMN. Muscle insulin sensitivity improved, but muscle NAD+ content did not rise. This was not a cognition, brain or lifespan trial. [5]
creatine
creatine: Avgerinos et al. (2018) assessed 281 people in 6 randomized studies. Some findings favored short-term memory and reasoning; attention, executive function and mental fatigue findings were mixed. This systematic review is not a meta-analysis reporting one Cohen’s d≈0.3–0.4 value. [6]
Dose information and research limits
This article presents selected source comparisons, not a complete clinical or independent medical review. Product, measurement and study population matter. A research dose is not a personal prescription; missing interaction records do not prove safety.
These substances are examples studied under the same topic; their combined efficacy and safe dosing schedules have not been established. Single-substance studies do not prove clinical synergy of a combination. Review the source profiles together with interaction warnings.
Sources
- Mattson MP, et al. (2008). Mitochondria in neuroplasticity and neurological disorders. Neuron, 60(5), 748–766. PubMed · PMID 19081372
- Beal MF. (2004). Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. Journal of Bioenergetics and Biomembranes, 36(4), 381–386. PubMed · PMID 15377876
- Mills KF, et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism, 24(6), 795–806. PubMed · PMID 28068222
- Parkinson Study Group QE3 Investigators, et al. (2014). A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurology, 71(5), 543–52. https://doi.org/10.1001/jamaneurol.2014.131 PubMed · PMID 24664227
- Yoshino M, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229. PubMed · PMID 33888596
- Avgerinos KI, et al. (2018). Effects of creatine supplementation on cognitive function of healthy individuals: a systematic review of randomized controlled trials. Experimental Gerontology, 108, 166–173. PubMed · PMID 29704637
- Chowanadisai W, et al. (2010). Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. The Journal of biological chemistry, 285(1), 142-52. PubMed · PMID 19861415
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Brain fog, concentration problems and fatigue do not by themselves diagnose mitochondrial dysfunction. These symptoms can have different causes; mechanistic research does not establish an individual need for supplements. Persistent symptoms or impairment of daily function warrant clinical assessment.
PQQ is a redox compound. Mitochondrial biogenesis and neuroprotection findings are mostly cellular or animal data; new brain mitochondria or BDNF-mediated cognitive benefit in humans have not been established.
These substances are examples studied under the same topic; their combined efficacy and safe dosing schedules have not been established. Single-substance studies do not prove clinical synergy of a combination. Review the source profiles together with interaction warnings.
Yoshino 2021: 25 postmenopausal women with prediabetes and overweight/obesity completed a 10-week randomized double-blind trial: 12 received placebo and 13 received 250 mg/day NMN. Muscle insulin sensitivity improved, but muscle NAD+ content did not rise. This was not a cognition, brain or lifespan trial.
Avgerinos et al. (2018) assessed 281 people in 6 randomized studies. Some findings favored short-term memory and reasoning; attention, executive function and mental fatigue findings were mixed. This systematic review is not a meta-analysis reporting one Cohen’s d≈0.3–0.4 value.